Argitalpenak (101) MANUEL FERNÁNDEZ MARTÍNEZ argitalpenak

2024

  1. Anti-alpha synuclein and anti-tau immunotherapies: Can a cocktail approach work?

    Parkinsonism and Related Disorders, Vol. 122

  2. DRD4 gene polymorphism and impulse control disorder induced by dopamine agonists in Parkinson's disease

    Annals of Clinical and Translational Neurology, Vol. 11, Núm. 8, pp. 2222-2229

  3. Enhanced quantitation of pathological α-synuclein in patient biospecimens by RT-QuIC seed amplification assays

    PLoS Pathogens, Vol. 20, Núm. 9

  4. Fluid and tissue biomarkers in Parkinson's disease: Immunodetection or seed amplification? Central or peripheral?

    Parkinsonism and Related Disorders, Vol. 121

  5. Mitochondrial DNA deletions in the cerebrospinal fluid of patients with idiopathic REM sleep behaviour disorder

    eBioMedicine, Vol. 102

2023

  1. Altered sleep and neurovascular dysfunction in alpha-synucleinopathies: the perfect storm for glymphatic failure

    Frontiers in Aging Neuroscience, Vol. 15

  2. Midbrain and pons MRI shape analysis and its clinical and CSF correlates in degenerative parkinsonisms: a pilot study

    European Radiology, Vol. 33, Núm. 7, pp. 4540-4551

2022

  1. Cell-free mitochondrial DNA deletions in idiopathic, but not LRRK2, Parkinson's disease

    Neurobiology of Disease, Vol. 174

  2. Combined CSF α-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again

    Parkinsonism and Related Disorders, Vol. 99, pp. 33-41

  3. Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study

    World Journal of Urology, Vol. 40, Núm. 10, pp. 2459-2466

  4. Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease

    Movement Disorders, Vol. 37, Núm. 5, pp. 1004-1015

  5. Increased Phospho-AKT in Blood Cells from LRRK2 G2019S Mutation Carriers

    Annals of Neurology, Vol. 92, Núm. 5, pp. 888-894

  6. Serum MicroRNAs Predict Isolated Rapid Eye Movement Sleep Behavior Disorder and Lewy Body Diseases

    Movement Disorders, Vol. 37, Núm. 10, pp. 2086-2098

2021

  1. Cross-sectional associations of cerebrospinal α-synuclein, tau and amyloid-β with dyskinesias, motor fluctuations, non-motor symptoms in a cohort of Parkinson's disease patients

    Journal of the Neurological Sciences

  2. Exome-wide rare variant analysis in familial essential tremor

    Parkinsonism and Related Disorders, Vol. 82, pp. 109-116

  3. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome

    Nature Communications, Vol. 12, Núm. 1

  4. Human-lineage-specific genomic elements are associated with neurodegenerative disease and APOE transcript usage

    Nature Communications, Vol. 12, Núm. 1

  5. Identification of sixteen novel candidate genes for late onset Parkinson’s disease

    Molecular Neurodegeneration, Vol. 16, Núm. 1

  6. Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease

    Annals of Neurology, Vol. 90, Núm. 1, pp. 35-42

  7. Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder

    npj Parkinson's Disease, Vol. 7, Núm. 1